연구동향 분석

파킨슨병의 생물표지자: 임상 및 생화학 생물표지자

이주영 마효일 김영은 2021년

논문상세정보
인용/피인용
' 파킨슨병의 생물표지자: 임상 및 생화학 생물표지자' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Alpha-Synuclein
  • Biomarkers
  • parkinson’s disease
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
364 0

0.0%

' 파킨슨병의 생물표지자: 임상 및 생화학 생물표지자' 의 참고문헌

  • Value of in vivo alpha-synuclein deposits in Parkinson’s disease: a systematic review and meta-analysis
    Tsukita K [2019]
  • Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson’s disease
    Hirayama M [2011]
  • Urate as a predictor of the rate of clinical decline in Parkinson disease
    Ascherio A [2009]
  • Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies
    Rossi M [2020]
  • The suppressive effect of dietary coenzyme Q10 on mitochondrial reactive oxygen species production and oxidative stress in chickens exposed to heat stress
    Kikusato M [2016]
  • The significance of alpha-synuclein, amyloid-beta and tau pathologies in Parkinson’s disease progression and related dementia
    Compta Y [2014]
  • The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder
  • The diagnostic and differential diagnosis utility of cerebrospinal fluid alpha-synuclein levels in Parkinson’s disease: a meta-analysis
    Zhou B [2015]
  • The concept of prodromal Parkinson’s disease
  • Tau protein, beta-amyloid(1)(-)(4)(2) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia
    Vranová HP [2014]
  • Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline
    Clinton LK [2010]
  • Submandibular gland is a suitable site for alpha synuclein pathology in Parkinson disease
    Shin J [2019]
  • Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease
    Wang Z [2020]
  • Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson’s disease
    Scalzo P [2010]
  • Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease
    Godau J [2011]
  • Serum IGF-1 is associated with cognitive functions in early, drug-naive Parkinson’s disease
    Picillo M [2017]
  • Role of Oxidative Stress in Parkinson’s Disease
    황온유 [2013]
  • Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis
    Sako W [2014]
  • Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra
    Howells DW [2000]
  • Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson’s disease
    Sohmiya M [2004]
  • Red blood cells are the major source of alpha-synuclein in blood
    Barbour R [2008]
  • Recent advances in biomarkers for Parkinson’s disease
    He R [2018]
  • Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC
    Groveman BR [2018]
  • REM sleep behavior disorder in early Parkinson’s disease predicts the rapid dopaminergic denervation
    Kim YE [2020]
  • Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients
  • Premotor and nonmotor features of Parkinson’s disease
    Goldman JG [2014]
  • Plasma tau protein and Abeta42 level as markers of cognitive impairment in patients with Parkinson’s disease
  • Plasma levels of alpha-synuclein, Abeta-40 and t-tau as biomarkers to predict cognitive impairment in Parkinson’s disease
    Chen NC [2020]
  • Plasma alpha-synuclein levels in patients with Parkinson’s disease:a systematic review and meta-analysis
    Bougea A [2019]
  • Phosphorylated alpha-synuclein in Parkinson’s disease: correlation depends on disease severity
    Stewart T [2015]
  • Phosphorylated alpha-synuclein in Parkinson’s disease
    Wang Y [2012]
  • Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease
    Foulds PG [2011]
  • Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses
  • Parkinson’s disease biomarkers based on alpha-synuclein
    Fayyad M [2019]
  • Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
    Majbour NK [2016]
  • Olfaction in Parkinson’s disease
    Doty RL [2007]
  • Nonmotor symptoms of Parkinson’s disease: prevalence and awareness of patients and families
    Cheon SM [2008]
  • Microbiome changes: an indicator of Parkinson’s disease?
    Haikal C [2019]
  • MicroRNA-4639is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson’s disease
    Chen Y [2017]
  • May serum levels of advanced oxidized protein products serve as a prognostic marker of disease duration in patients with idiopathic Parkinson’s disease?
  • MDS clinical diagnostic criteria for Parkinson’s disease
    Postuma RB [2015]
  • Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease
    Hall S [2016]
  • Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease
    Zhang J [2013]
  • Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
  • Invited article: nervous system pathology in sporadic Parkinson disease
    Braak H [2008]
  • Increased risk of Parkinson’s disease after depression: a retrospective cohort study
  • Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study
    Jennings D [2014]
  • Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease
    Postuma RB [2012]
  • Identification of circulating microRNAs for the differential diagnosis of Parkinson’s disease and multiple system atrophy
  • Homocysteine levels in Parkinson’s disease: is entacapone effective?
    Kocer B [2016]
  • Glucocerebrosidase defects as a major risk factor for Parkinson’s disease
    Avenali M [2020]
  • Fundamental limit of alpha-synuclein pathology in gastrointestinal biopsy as a pathologic biomarker of Parkinson’s disease: comparison with surgical specimens
    Shin C [2017]
  • Frequency of bowel movements and the future risk of Parkinson’s disease
    Abbott RD [2001]
  • Finding useful biomarkers for Parkinson’s disease
  • Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson’s disease
  • Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death
  • Etiology and pathogenesis of Parkinson disease
    Schapira AH [2009]
  • Elevated plasma homocysteine levels in L-dopa-treated Parkinson’s disease patients with dyskinesias
  • Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson’s disease
    Parnetti L [2014]
  • Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson’s disease: a systematic review and meta-analysis
    Eusebi P [2017]
  • Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
  • Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid
    Shahnawaz M [2017]
  • Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease
    El-Agnaf OM [2006]
  • Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease
    Tokuda T [2010]
  • Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease
    Wang X [2015]
  • Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study
    Iranzo A [2021]
  • Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson’s disease
    Martins M [2011]
  • Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson’s disease
    Kang UJ [2019]
  • Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms
    Lebouvier T [2010]
  • Clinical implication of REM sleep behavior disorder in Parkinson’s disease
    Kim YE [2014]
  • Changes of cerebrospinal fluid Abeta42, t-tau, and p-tau in Parkinson’s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis
    Hu X [2017]
  • Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease
  • Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease
    Parnetti L [2014]
  • Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
    Shi M [2011]
  • Cerebrospinal fluid biochemical studies in patients with Parkinson’s disease: toward a potential search for biomarkers for this disease
  • Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis
    Gao L [2015]
  • CSF tau and tau/Abeta42 predict cognitive decline in Parkinson’s disease
    Liu C [2015]
  • CSF biomarkers for early diagnosis of synucleinopathies: focus on idiopathic RBD
    Liguori C [2019]
  • CSF and blood biomarkers for Parkinson’s disease
    Parnetti L [2019]
  • CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease
    Siderowf A [2010]
  • CSF alpha-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders
    Mondello S [2014]
  • CSF Aβ(42) and tau in Parkinson’s disease with cognitive impairment
    Montine TJ [2010]
  • Blinded RT-QuIC analysis of alpha-synuclein biomarker in skin tissue from Parkinson’s disease patients
    Manne S [2020]
  • Association of olfactory dysfunction with risk for future Parkinson’s disease
    Ross GW [2008]
  • Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease
    Irizarry MC [2005]
  • Alzheimer’s disease
    Ballard C [2011]
  • Alpha-synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson’s disease patients
    Manne S [2020]
  • Alpha-synuclein is phosphorylated in synucleinopathy lesions
    Fujiwara H [2002]
  • Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies
    Fairfoul G [2016]
  • Alpha-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson’s Disease
    Waragai M [2010]
  • Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification
    Jaffe JD [2008]
  • Accuracy of diagnosis in patients with presumed Parkinson’s disease
    Meara J [1999]
  • Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders
    Hall S [2012]
  • A targeted proteomics-based pipeline for verification of biomarkers in plasma
  • A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes
  • 8-OHdG in cerebrospinal fluid as a marker of oxidative stress in various neurodegenerative diseases